medigraphic.com
Colegio de Medicina Interna de México.

2023, Número 3

<< Anterior Siguiente >>

Med Int Mex 2023; 39 (3)


Evaluación de la función renal y tiroidea en pacientes diabéticos e hipertensos en Tepic, Nayarit, México

Delgado-Mejía M, Delgado-Astorga C, Paredes-Casillas P, González-González E, Calvo-Vargas C

Idioma: Español
Referencias bibliográficas: 46
Paginas: 440-447
Archivo PDF: 204.77 Kb.


RESUMEN

Objetivo: Evaluar la función renal en pacientes con diabetes mellitus tipo 2 e hipertensión arterial sistémica comparando las cifras de depuración de creatinina obtenidas por la fórmula de Cockroft-Gault y con la depuración de creatinina en orina de 24 horas.
Materiales y Métodos: Estudio observacional y descriptivo realizado de enero de 2018 a enero de 2020, en el que se evaluaron pacientes con diagnóstico de diabetes mellitus tipo 2 e hipertensión arterial sistémica, de uno y otro sexo, mayores de 30 años. Se evaluó la función renal con la fórmula de Cockroft-Gault contra la medición de depuración de creatinina en orina de 24 horas en laboratorio. A todos los pacientes se les practicaron pruebas adicionales de la función tiroidea.
Resultados: Se evaluaron 111 pacientes con diabetes tipo 2 (41 hombres y 70 mujeres), de los que 99 (89%), además, tenían diagnóstico de hipertensión arterial. Se encontró una correlación de las pruebas de 0.659, valor de t 2.67 y valor de p de -0.001, lo que indica que la fórmula de Cockroft-Gault y la de depuración de creatinina en 24 horas pueden dar precisión en los resultados. De los 111 pacientes, 35 tenían pruebas anormales de la función tiroidea.
Conclusiones: La fórmula Cockcroft-Gault es útil para dar seguimiento a la función renal de los pacientes, ante la falta de la determinación de depuración de creatinina en orina de 24 horas en laboratorio.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kasper, Fauci, Hauser, Longo, Jameson, Loscalzo, Harrison.Principles of Internal Medicine. 19ª ed. 2016; vol. 2.

  2. Van den Berg BM, Wang G, Boels MGS, Avramut MC, etal. Glomerular function and Structural integrity dependon hyaluronan synthesis by glomerular endothelium.J Am Soc Nephrol 2019; 30:1886-97. doi: 10.1681/ASN.2019020192.

  3. Assady S, Benzing T, Kretzler M, Skorecki KL. Glomerularpodocytes in kidney health and disease. Lancet 2019; 393:856-8. https://doi.org/10.1016/S0140-6736(18)33000-9.

  4. Fissell WH, Miner JH. What is the glomerular ultrafiltrationbarrier? J Am Soc Nephrol 2018; 29: 2262-4. 10.1681/ASN.2018050490.

  5. GBD Chronic Kidney Disease Collaboration. Global, regional,and national burden of chronic kidney disease,1990-2017: A systematic analysis for the Global Burdenof Disease Study 2017. Lancet 2020; 395: 709-33. doi:10.1016/S0140-6736(20)30045-3.

  6. Adler AL, Stevens RJ, Manley SE, Holman RR. Developmentand progression of nephropathy in type 2 diabetes:The United Kingdom Prospective Diabetes Study (UKPDS64). Kidney Int 2003; 63: 225-32. doi: 10.1046/j.1523-1755.2003.00712.x.

  7. Alegre-Díaz J, Herrington W, López-Cervantes M, RamírezR, et al. Diabetes and cause-specific mortality in MexicoCity. N Engl J Med 2016; 375: 1961-71.

  8. Astudillo O. Country in focus: Mexico’s growing obesity problem.Lancet Diabetes Endocrinol 2014; 2: 15-16. https://doi.org/10.1016/S2213-8587(13)70160-8.

  9. Rawshani A, Rawshani A, Franzen S, Eliasson B, et al. Riskfactors, mortality, and cardiovascular outcomes in patientswith type 2 diabetes. N Engl J Med 2018; 379: 633- 44. doi:

  10. 10.1056/NEJMoa1800256.10. Rawshani A, Rawshani A, Gudbjörnsdottir S. Mortality andcardiovascular disease in type 1 and type 2 diabetes. N EnglJ Med 2017; 376: 1407-18. doi: 10.1056/NEJMc1706292.

  11. Menke A, Casagrande S, Geisss L, Cowie-CC. Prevalenceof and trends in diabetes among adults in the UnitedStates, 1988-2012. JAMA 2015; 314: 1021-9. doi: 10.1001/jama.2015.10029.

  12. Ettehad D, Emdin CA, Kiran A, Anderson SG, et al. Bloodpressure lowering for prevention of cardiovascular diseaseand death: a systematic review and meta- analysis. Lancet2016; 387: 957-67. doi: 10.1016/S0140-6736(15)01225-8.

  13. Colchero MA, Popkin BM, Rivera JA, Ng SW. Beverage purchasesfrom stores in Mexico under the excise tax on sugarsweetened beverages: observational study. BMJ 2016; 352:h6704. https://doi.org/10.1136/bmj.h6704.

  14. Calvo-Vargas CG, Rubio-Guerra AF, Galarza-Delgado D,García C, Delgado-Mejía M. Eficacia del valsartán y la hidroclorotiazidaen el tratamiento de la hipertensión arterialesencial. Estudio realizado mediante la automedición apréstamo de la presión arterial. Med Int Mex 2002; 18(2): 67-74.

  15. Hayward RA, Reaven PD, Witala WL, Bahn GD, et al. Followupof glycemic control and cardiovascular outcomes intype 2 diabetes. N Engl J Med 2015; 372: 2197-206. doi:10.1056/NEJMoa1414266.

  16. Delgado-Mejía M, Delgado C, Ávalos T, Paredes P, GonzálezE. Control and evaluation of microalbuminuria in a populationof the state of Nayarit, Mexico. Study conductedby self—measurement on loan of blood pressure. MedInt Mex 2018; 34 (6): 864-873. https://doi.org/10.24245/mim.v34i6.2617.

  17. Logue J, Walker JJ, Leese G, Lindsay R, et al. Associationbetween BMI measured within a year after diagnosis oftype 2 diabetes and mortality. Diabetes Care 2013; 36:887-93. doi: 10.2337/dc12-0944.

  18. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA,et al, for STAMPED Investigators. Bariatric surgery versusintensive medical therapy for diabetes — 3-year outcomes.N Engl J Med 2014; 370: 2002-13. DOI: 10.1056/NEJMoa1401329.

  19. Brethauer PR, Aminian A, Romero-Talamas H, et al. Candiabetes be surgically cured? Long-term metabolic effectsof bariatric surgery in obese patients with type 2 diabetesmellitus. Ann Surg 2013; 258: 628-36. doi: 10.1097/SLA.0b013e3182a5034b.

  20. Ikramuddin S, Korner J, Lee WJ, Connett JE, et al. Roux-en-Ygastric bypass vs Intensive Medical management for thecontrol of type 2 diabetes, Hypertension, and hyperlipidemia:the Diabetes Surgery study randomized clinical trial.JAMA 2013; 309: 2240-9. doi: 10.1001/jama.2013.5835.

  21. Kaplan NM. Clinical hypertension. Baltimore: Williams &Wilkins, 2014.

  22. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, et al. Semaglutideand cardiovascular outcomes in patients with type2 diabetes. N Engl J Med 2016; 375: 311-22. DOI: 10.1056/NEJMoa1607141.

  23. Stanton RC. Clinical challenges in diagnosis and managementof diabetic kidney disease. Am J Kidney Dis 2014; 63(Suppl 2): S3-21. doi: 10.1053/j.ajkd.2013.10.050.

  24. Zinman B, Wanner C, Lachin JM, Fitchett D, et al. Empagliflozin,cardiovascular outcomes, and mortality in type 2diabetes. N Engl J Med 2015; 373: 2117-28. DOI: 10.1056/NEJMoa1504720.

  25. Kelsey MM, Zeitler PS. Insulin resistance of puberty. CurrDiab Rep 2016; 16: 64. doi: 10.1007/s11892-016-0751-5.

  26. Stringhini S, Batty GD, Bovet P, Shipley MJ, et al. Associationof life-course socioeconomic status with chronicinflammation and type2 diabetes risk: tha Witehall 11prospective cohort study. Plus Med 2013; 10 (7): e1001479.doi: 10.1371/journal.pmed.1001479.

  27. The ACCORD Study Group. Nine-year effects of 3.7 yearsof intensive glycemic control on cardiovascular outcomes.Diabetes Care 2016; 39: 701-708. doi: 10.2337/dc15-2283.

  28. 29. Tancredi M, Rosengren A, Svensson AM, KosiborodM, et al. Excess mortality among persons with type 2diabetes. N Engl J Med 2015; 373: 1720-32. DOI: 10.1056/NEJMoa1504347.

  29. Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, et al.Intensive glucose control in patients with type 2 diabetes— 15-year follow-up. N Engl J Med 2019; 380: 2215- 24.DOI: 10.1056/NEJMoa1806802.

  30. Diabetes Control and Complications Trial (DCCT)/Epidemiologyof Diabetes Interventions and Complications (EDIC)Study Research Group. Intensive diabetes treatment andcardiovascular outcomes in type 1 diabetes: the DCCT/EDICStudy 30-year follow-up. Diabetes Care 2016; 39: 686-93.doi: 10.2337/dc15-1990.

  31. Levey AS, Coresh J, Balk E, Kausz AT, et al. National KidneyFoundation practice guidelines for chronic kidney diseaseevaluation, classification, and stratification. Ann InternMed 2003; 139: 137-147. doi: 10.7326/0003-4819-139-2-200307150-00013.

  32. Dwyer JP, Parvging HH, Ravid M, RamuzziG, Lewis JB. Renaldysfunction in the presence of normoalbuminuria in type2 diabetes; results from the DEMAND study. CardiorenalMed 2012; 2 (1): 1-10. doi: 10.1159/000333249.

  33. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, PatelA. Blood pressure lowering in type 2 diabetes : a systematicreview and meta-analysis. JAMA 2015; 313 (6): 603-615.doi: 10.1001/jama.2014.18574.

  34. Benzing T, Salant D. Insights into glomerular filtrationand albuminuria. N Engl J Med 2021; 384: 1437-46. doi:10.1056/NEJMra1808786.

  35. Hu Y, Zong G, Liu G, Wang M, et al. Smoking cessation,weight change, type 2 diabetes , and mortality. N Engl JMed 2018; 379: 623-32. DOI: 10.1056/NEJMoa1803626.

  36. Twig G, Yaniv G, Levine H, Leiba A, et al. Body-mass indexin 2.3 million adolescents and cardiovascular deathin adulthood . N Engl J Med 2016; 374: 2430-40. DOI:10.1056/NEJMoa1503840.

  37. Shah RV, Murphy VL, Colangelo LA, Reis J, et al. Associationof fitness in young adult-hood with survival and cardiovascularrisk: the Coronary Artery Risk Development inYoung Adults (CARDIA) Study. JAMA 2016; 176: 87-95.doi: 10.1001/jamainternmed.2015.6309.

  38. Appel GB, Radhakrishnan J, Avram MM, Defronzo RA, etal. Analysis of metabolic parameters as predictors of riskin the RENAAL Study. Diabetes Care 2003; 26: 1402-1407.doi: 10.2337/diacare.26.5.1402.

  39. Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The globalepidemiology of diabetes and kidney disease. AdvChronic Kidney Dis 2018; 25 (2): 121-132. https://doi.org/10.1053/j.ackd.2017.10.011.

  40. Bjerregaard JG, Jensen BW, Angquist L, Osler M, et al. Changein overweight from childhood to early adulthood andrisk of type 2 diabetes. 2018; 378: 1302-12. DOI: 10.1056/NEJMoa1713231.

  41. Aarestrup J, Bjerregaard LG, Gamborg M, Angquist L, et al.Tracking of body mass index from 7 to 69 years of age. Int JObes (Lond) 2016; 40: 1376-83. doi: 10.1038/ijo.2016.88.

  42. Zimmermann E, Bjerregaard LG, Gamborg M, Vaag AA, etal. Childhood body mass index and development of type2 diabetes throughout adult life: a large-scale Danish cohortstudy. Obesity (Silver-Spring) 2017; 25: 965-71. doi:10.1002/oby.21820.

  43. Jali MV, Kambar S, Jali SM, Pawar N, Nalawade P. Prevalenceof thyroid dysfunction among type 2 diabetes mellituspatients. Diabetes Metab Syndr 2016. doi: 10.1016/j.dsx.2016.12.017.

  44. Han C, He X, Xia X, Li Y. Subclinical hypothyroidism andtype 2 diabetes: Systematic review and meta-analysis.PLoS One 2015; 10 (8): e135233. doi: 10.1371/journal.pone.0135233.

  45. Bishop M. Clinical chemistry. Textbook of Principles. Techniquesand Correlations. 2017.

  46. Tietz. Textbook of clinical chemistry and molecular diagnostics.2017.




2020     |     www.medigraphic.com